Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine
December 08, 2015 at 09:00 AM EST
Nektar Therapeutics (NASDAQ: NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and ...